Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine
Rob J Center, Irene Boo, Lilian Phu, Joey McGregor, Pantelis Poumbourios, Heidi E Drummer
JOURNAL OF BIOLOGICAL CHEMISTRY | AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC | Published : 2020
The E2 glycoprotein of hepatitis C virus (HCV) is the major target of broadly neutralizing antibodies (bNAbs) that are critical for the efficacy of a prophylactic HCV vaccine. We previously showed that a cell culture-derived, disulfide-linked high-molecular-weight (HMW) form of the E2 receptor-binding domain lacking three variable regions, Δ123-HMW, elicits broad neutralizing activity against the seven major genotypes of HCV. A limitation to the use of this antigen is that it is produced only at low yields and does not have a homogeneous composition. Here, we employed a sequential reduction and oxidation strategy to efficiently refold two high-yielding monomeric E2 species, D123 and a disulf..View full abstract
Awarded by National Health and Medical Research Council
This study was supported by National Health and Medical Research Council Grants GNT1041897, GNT1146082, and GNT1080045 and the Australian Centre for HIV and Hepatitis Virology. The authors declare that they have no conflicts of interest with the contents of this article.